Introduction
============

N-type calcium channels (Ca~v~2.2) are highly distributed at nerve terminals and on cell bodies of dorsal root ganglia (DRG) neurons, where they regulate the release of pain-related neuropeptides. Pharmacology and genetic studies showed that Ca~v~2.2 inhibiting activity was an effective way to manage or alleviate symptoms of inflammatory, chronic and neuropathic pain ([@B11]; [@B9]; [@B21], [@B22]; [@B18]; [@B17]; [@B1]; [@B27]). Ca~v~2.2 antagonists have therefore long been considered as potential analgesics ([@B10]; [@B16]; [@B12]; [@B30]; [@B20]; [@B23]; [@B24]). Indeed, a synthetic form of ω-conotoxin MVIIA, a peptide toxin isolated from the marine cone snail, genus *Conus*, that potently inhibits Ca~v~2.2, is in clinical use (marked as ziconotide) to treat severe and chronic pain ([@B23]). However, ziconotide can only be delivered intrathecally and even so has numerous serious adverse effects. Therefore, it is clearly desirable for development of new Ca~v~2.2 antagonists.

*Valeriana jatamansi* Jones distributed widely in China and some other Asian countries ([@B16]). The roots and rhizomes of this plant is a well-known herbal medicine "Zhizhuxiang" in the Chinese Pharmacopoeia for treating abdominal pain ([@B7]). Several clinically used medicines for treating abdominal pain in the Chinese market, such as "Xiangguo Jianxiao Pian," are prepared by Zhizhuxiang as a main component. However, the chemical basis and molecular targets of *V. jatamansi* Jones for the treatment of abdominal pain remain unrevealed.

Inspired by the analgesic effect of *V. jatamansi* Jones, bioassay-guided isolation and characterization of the active constituents of the plant that target Ca~v~2.2 were carried out herein. Initially, the ethanol extract and the EtOAc, *n*-BuOH and H~2~O fractions of the plant were tested for their inhibition of Ca~v~2.2. Subsequent function-guided phytochemical studies on the active EtOAc part resulted in the isolation and identification of thirteen iridoids (**1**--**13**) and four sesquiterpenes (**14**--**17**) (**Figure [1](#F1){ref-type="fig"}**), including two new valepotriates, namely jatamanvaltrate T and U (**1**--**2**). The inhibitory activities on Ca~v~2.2 of all the compounds were tested. Among them, the new compound **1** and the main constituent **3** (8.45 g out of 32.5 kg of plant material) exhibited significant inhibitory effects on Ca~v~2.2 with EC~50~ values of 3.3 and 4.8 μM, respectively. In addition, compound **1** and **3** showed noticeable selectivity over Ca~v~1.2, Ca~v~2.1 and Ca~v~3.1 VGCCs and Kv1.2, Kv2.1, Kv3.1 and BK potassium channels.

![Chemical structures of compounds **1--17**.](fphar-09-00885-g001){#F1}

Materials and Methods
=====================

General Experimental Procedures
-------------------------------

Optical rotations were measured with a JASCO model 1020 polarimeter (Horiba, Tokyo, Japan). UV spectra were recorded on a Shimadzu UV-2401PC spectrophotometer (Shimadzu, Kyoto, Japan) and IR (KBr) spectra were obtained using a Bruker Tenor 27 FT-IR spectrophotometer (Bruker Optics GmbH, Ettlingen, Germany). ESIMS and HRESIMS were performed on an Agilent G6230 TOF MS (Agilent Technologies, Palo Alto, CA, United States) or an API QSTAR time-of-flight spectrometer (AB-MDS Sciex, Concord, ON, Canada) or a VG Autospec-3000 spectrometer (VG, Manchester, United Kingdom). 1D and 2D NMR spectra were recorded on Bruker AM-400 and DRX-500 spectrometer (Bruker, Bremerhaven, Germany) with TMS as the internal standard. Chemical shifts (δ) are expressed in ppm with reference to the solvent signals. MPLC was run on a Dr-Flash-S MPLC system (Lisui, Suzhou, China). Silica gel (200-300 mesh) for column chromatography (CC) and TLC was obtained from Qingdao Marine Chemical Factory, Qingdao, China. Sephadex LH-20 was purchased from Amersham Biosciences, Sweden. RP-C18 gel (40--63 μm, Merck, Darmstadt, Germany) and MCI gel (75--150 μm, Mitsubishi Chemical Corporation, Japan). Fractions were monitored by TLC (GF254, Qingdao Haiyang, Qingdao, China), and spots were visualized by sprayed with 5% sulfuric acid in EtOH, followed by heating.

Plant Material
--------------

The roots and rhizomes of *V. jatamansi* were collected at Kunming, Yunnan Province, People's Republic of China, in July 2012, and identified by Prof. En-De Liu, and a voucher specimen (KUN NO. 0864803), has been deposited in State Key Laboratory of Phytochemistry and Plant Resource in West China, Kunming Institute of Botany, The Chinese Academy of Sciences, Kunming, China.

The Preparation of Crude Extract and Fractions
----------------------------------------------

The air-dried roots (450 g) of *V. jatamansi* were powdered and extracted with 95% ethanol at room temperature (3L × four times, each time 24 h) with occasional shaking. The extracted was filtered and concentrated with a rotary evaporator at 45--50°C, giving 75.5 g residues (The yield is approximate 16.8%). The ethanol extract (43.62 g) was suspended in distilled (600 ml) water and partitioned successively with EtOAc and *n*-BuOH (five times, each time 0.5 h), then evaporated on rotary evaporator to afford EtOAc-soluble part (12.73 g) and *n*-BuOH layer (5.38 g). The H~2~O-soluble part was passed through a macroporous absorbent resin (D-101) with H~2~O and ethanol, then concentrated under reduced pressure to obtain H~2~O layer (0.51 g). The EtOAc part was subjected to silica gel column chromatography eluted with a gradient of petroleum ether/acetone (1:0-0:1, v/v) to afford 9 fractions (Fr.1--Fr.9).

Extraction and Isolation
------------------------

Based on the observed effect with the EtOAc portion on Ca~v~2.2, further extraction and isolation of the EtOAc portion were carried out herein.

The air-dried, powdered roots of *V. jatamansi* (32.50 kg) were extracted three times with 95% EtOH (3 × 60 L, each 28 h) at room temperature. The combined EtOH extracts were concentrated in vacuum to afford a crude residue (3.65 kg), which was then suspended in water (4.0 L) and partitioned with EtOAc (4.0 L × 5). Then got the EtOAc part (1.72 kg) and chromatographed on a silica gel column chromatography (CC, 200--300 mesh), eluting with a gradient of petroleum ether-acetone (1:0-0:1) to give nine fractions (Fr.1--Fr.9). Fr.1 (192.4 g) was resubmitted to silica gel CC (petroleum ether-acetone gradient, 1:0-10:1) and then purified by Sephadex LH-20 column (MeOH) to yield compound **5** (94.0 mg) and **17** (17 mg). Similarly, **8** (53 mg) and **6** (135 mg) were got from Fr.2 (41.10 g). Fr.3 (55.50 g) was decolorized on a MCI gel (MeOH-H~2~O gradient, 60:40-95:5), then subjected to MPLC (RP-18 gel, MeOH-H~2~O gradient, 40:60-90:10) and separated by Sephadex LH-20 column (MeOH) to give **7** (246 mg) and **10** (34 mg). The bioactive Fr.4 (100.30 g) was chromatographed on silica gel CC (200--300 mesh) (petroleum ether-acetone, 50:1-1:1) to yield 4 fractions (Fr.4.1--Fr.4.4). Fraction 4.2 (28.3 g) was applied to a MCI gel (MeOH-H~2~O gradient, 60:40-85:15), then by repeated silica gel CC (petroleum ether-acetone, 20:1-5:1) to obtain **14** (70 mg) and **15** (1.65 g), then further by RP-C18 (MeOH-H~2~O gradient, 50:50-85:15) and followed by Sephadex LH-20 (MeOH) to give **1** (148 mg) and **9** (95 mg). Fr.4.3 (22.017 g) was successively separated by MPLC (MeOH-H~2~O gradient, 30:60-50:50) and repeated silica gel CC (petroleum ether-EtOAc, 10:1-5:1), purified by Sephadex LH-20 (MeOH) to obtain **2** (81 mg) and **11** (5 mg). The bioactive Fr.6 (193.70 g) was passed through a silica gel CC and eluted with a gradient of petroleum ether-acetone (20:1-0:1) to yield 11 fractions (Fr.6.1--Fr.6.11). Fr.6.8 (70.0 g) was subjected to silica gel CC (petroleum ether-acetone gradient, 10:1-0:1) to afford 8 sub-fractions (Fr.6.8.1--Fr.6.8.8). Fr.6.8.5 (33.64 g) was repeatedly subjected to silica gel CC (petroleum ether-acetone gradient, 10:1-0:1), then purified by Sephadex LH-20 column (MeOH) to give **3** (8.45 g) and **4** (50 mg) and **16** (60 mg). Fr.6.9 (73.5 g) was treated as Fr.6.8.5 and get compounds **12** (20 mg) and **13** (51 mg).

Physical and Spectroscopic Data of New Compounds
------------------------------------------------

### Jatamanvaltrate T (1)

Colorless oil, ${\lbrack a\rbrack}_{D}^{23}$ = +152.60 (*c* 0.26, MeOH, **Supplementary Figure [S12](#SM1){ref-type="supplementary-material"}**). UV (MeOH) λ~max~ (log 𝜀~max~): 255 (5.22) nm (**Supplementary Figure [S11](#SM1){ref-type="supplementary-material"}**); IR (KBr) ν~max~ (cm^-1^): 3441, 2963, 2875, 1742, 1640, 1467, 1371, 1294, 1250, 1187, 1166, 1101, 1027, 963 cm^-1^; ^1^H NMR and ^13^C NMR data, see **Table [1](#T1){ref-type="table"}**; positive ESIMS m/z 647 \[M + Na\]^+^; HRESIMS m/z 647.3040 \[M + Na\]^+^ (calculated for C~32~H~48~O~12~Na, 647.3043).

###### 

^1^H NMR (400 MHz) and ^13^C NMR (100 MHz) data of compounds 1--2 in CD~3~OD.

      1                     2                                 
  --- --------------------- ----------- --------------------- -----------
  1   6.11, d (10.0)        94.0, CH    6.12, d (10.1)        94.0, CH
  3   6.78, s               149.5, CH   6.77, s               149.4, CH
  4                         110.4, C                          110.4, C
  5                         140.6, C                          140.7, C
  6   5.76, dd (2.6, 2.5)   118.6, CH   5.74, dd (2.7, 2.6)   118.4, CH
  7   5.48, d (2.7)         84.5, CH    5.49, d (2.7)         84.5, CH
  8                         80.6, C                           80.6, C
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### Jatamanvaltrate U (2)

White amorphous powder, ${\lbrack a\rbrack}_{D}^{23}$ = +131.61 (*c* 0.45, MeOH) (**Supplementary Figure [S22](#SM1){ref-type="supplementary-material"}**). UV (MeOH) λ~max~ (log 𝜀~max~):: 255 (4.59) nm (**Supplementary Figure [S21](#SM1){ref-type="supplementary-material"}**); IR (KBr) ν~max~ (cm^-1^): 3444, 2923, 1733, 1642, 1467, 1381, 1296, 1260, 1183, 1154, 1101, 1082, 1016, 987 cm^-1^; ^1^H NMR and ^13^C NMR data, see **Table [1](#T1){ref-type="table"}**; positive ESIMS m/z 701 \[M + Na\]^+^; HRESIMS m/z 701.4234 \[M + Na\]^+^ (calculated for C~38~H~62~O~10~Na, 701.4241).

Bioassay
--------

### Oocyte Preparation and Expression

Oocytes were obtained from adult *Xenopus* by digesting its ovarian lobes with collagenase A (sigma) for 2--3 h under 180 rpm shaking in OR2 \[MgCl~2~ (1 mM), NaCl (82.4 mM), KCl (2.5 mM), HEPES (5 mM) and NaOH (pH 7.6)\]. The best Stages V--VI oocytes were selected, injected with cRNA (50--100 ng), and then incubated at 18°C for 3--6 days depending on cRNA expression in ND96 \[CaCl~2~ (1.8 mM), MgCl~2~ (1 mM), NaCl (96 mM), KCl (2.5 mM), HEPES (5 mM), streptomycin (100 μg/mL), penicillin (100 units/mL) and NaOH (pH 7.6)\].

### HEK 293T Cell Culture and Expression

Human embryonic kidney (HEK) 293T cells were grown in DMEM (HyClone) plus 10% newborn calf serum (Gibco) and streptomycin (0.1 mg/ml)/penicillin (100 U/ml) (Biological Industries). The cells were transiently transfected with pCDNA3.1-α~2~δ, pCDNA3.1-β~3~, pCDNA3.1-EGFP and pCDNA3.1-N type plasmids together using LipoD293^TM^ (SignaGen Laboratories) and recorded in 48 h.

### Electrophysiology

All experiments were performed at 20--22°C. Whole-oocyte recordings by performed with two-electrode voltage clamp (TEVC). Electrodes were filled with KCl (3 mM) and had resistances of 0.3--1 MΩ. The bath solution used to record calcium channel currents contained KCl (2 mM), BaCl~2~ (1.8 mM), NaOH (50 mM), Ba(OH)~2~ (40 mM) and HEPES (5 mM). pH 7.4 was adjusted with methanesulfonic acid and the solution was filtered. L-type (Ca~v~1.2), N-type (Ca~v~2.2), and P/Q-type (Ca~v~2.1) calcium channel currents were evoked from a holding potential of -80 mV by 50-ms depolarizations ranging from -30 to 70 mV in 10-mV increments at 3-s intervals. Currents through T-type (Ca~v~3.1) calcium channels were elicited by voltage pulses (50 ms) from -50 to 60 mV with a holding potential of -80 mV in 10-mV increments at 3-s intervals. Kv1.1 currents were recorded from a holding potential of -80 mV by 200-ms depolarizations ranging from -60 to 60 mV in 10-mV increments at 15-s intervals. Kv2.1 and Kv3.1 currents were obtained from a holding potential of -80 mV by 200-ms depolarizations ranging from -40 to 60 mV in 10-mV increments at 15-s intervals. BK channel currents were obtained from a holding potential 0f -50 mV by 60-ms depolarization ranging from 0 to 100 mV in 10-mV increments at 3-s intervals. All the currents were sampled and filtered, respectively.

In whole-cell recordings of HEK 293T cells, pipettes were fabricated from borosilicate glass (World Precision Instruments) using a micropipette puller (P-1000, Sutter Instrument), and were fire-polished to resistances of ∼3 MW. Whole-cell currents were elicited by 20-ms voltage steps from -60 to 80 mV with 10-mV increments, with a holding potential of -80 mV. Currents were amplified by Axopatch 200B and digitized by Digidata 1440A (Molecular Devices). Currents were low-pass filtered at 2 kHz and sampled at 10 kHz. The extracellular solutions contained (in mM) 5 CsCl, 10 BaCl~2~, 140 TEA.Cl, 10 Glucose and 10 HEPES. pH was adjusted to 7.4 with CsOH. The intracellular solutions contained (in mM) 4 MgCl~2~, 140 CsCl, 10 EGTA and 10 HEPES (pH 7.4 adjusted with CsOH).

The effect on Ca~v~2.2 of the ethanol extract (0.01 mg/ml) and the EtOAc, *n*-BuOH and H~2~O soluble parts (0.01 mg/ml) of the EtOH extract was tested by TEVC of *Xenopus* oocytes (**Supplementary Figure [S23](#SM1){ref-type="supplementary-material"}**). The EtOAc-soluble part (**Supplementary Figure [S24](#SM1){ref-type="supplementary-material"}**), which exhibited a stronger inhibitory activity, was subjected to silica gel column chromatography to produce 9 fractions. All of the fractions (0.01 mg/ml), together with the isolates (**1**--**17**) from the fractions, were tested for their inhibitory effects on Ca~v~2.2, with a concentration of 10 μM (**1** and **3**) or 30 μM (**2**, and **4**--**17**). Compounds **1** and **3** were further tested for their activities on Ca~v~1.2, Ca~v~2.1 and Ca~v~3.1 VGCCs (10 μM) and on Kv1.2, Kv2.1, Kv3.1 and BK potassium channels (30 μM) (**Supplementary Figure [S25](#SM1){ref-type="supplementary-material"}**).

In a positive control experiment, the effect on Ca~v~2.2 of 100 μM CdCl~2~ and 0.2--1.0 μM ω-conotoxin MVIIA was tested by TEVC in *Xenopus* oocytes and by whole-cell recording in HEK 293T cells.

### Data Analysis and Statistics

Data acquisition and analysis of the whole-oocyte recordings were carried out by using pClamp 10 (Molecular Devices Corporation, San Jose, CA, United States). Data fitting and statistical analyses were performed by PRISM 5.0 (GraphPad Software Inc., San Diego, CA, United States). EC~50~ values and Hill slopes were determined by fitting the data points to a sigmoidal dose-response equation (*Y* = Min + (Max-Min)/(1+10ˆ((LogEC50-*X*)^∗^*n*))), where *Y* is % Inhibition, *X* is the concentration of the compounds, Min is minimal inhibition, Max is maximum inhibition, and *n* is the Hill coefficient. All data were presented as mean ± SEM, and statistical analysis was performed using Student's *t*-test. *P*-values of \< 0.05 were considered as significant, and levels of significance were marked by asterisks (^∗∗^*P* \< 0.01, ^∗^*P* \< 0.05).

Results and Discussion
======================

Structural Elucidation of Isolated Compounds
--------------------------------------------

Jatamanvaltrate T (**1**) was obtained as colorless oil with the molecular formula of C~32~H~48~O~12~ assigned by positive HRESIMS (**Supplementary Figure [S1](#SM1){ref-type="supplementary-material"}**) at m/z 647.3040 \[M + Na\]^+^ (calcd for C~32~H~48~O~12~Na, 647.3043), indicating nine degrees of unsaturation. The IR absorption (**Supplementary Figure [S10](#SM1){ref-type="supplementary-material"}**) bands at 3441, 1742, and 1640 cm^-1^ revealed the presence of hydroxy, ester carbonyl, and double bond groups, respectively. The ^1^H NMR and ^13^C-NMR spectroscopic data (**Table [1](#T1){ref-type="table"}** and **Supplementary Figures [S2](#SM1){ref-type="supplementary-material"}--[S4](#SM1){ref-type="supplementary-material"}**) displayed signals for two trisubstituted olefinic bonds \[δ~H~ 6.78 (s, H-3); δ~C~ 149.5 (d, C-3) and 110.4 (s, C-4); δ~H~ 5.76 (dd, *J* = 2.6, 2.5 Hz, H-6); δ~C~ 118.6 (d, C-6) and 140.6 (s, C-5)\], a hemiketal methine \[δ~H~ 6.11 (d, *J* = 10.0 Hz), H-1); δ~C~ 94.0 (d, C-1)\], and two oxymethylenes \[δ~H~ 4.39, 4.35 (each d, *J* = 11.3 Hz, H-10), 4.77 (d, *J* = 11.4 Hz, H-11a) and 4.65 (d, *J* = 12.3 Hz, H-11b); δ~C~ 67.5 (t, C-10) and 62.0 (t, C-11)\]. These data, together with the resonances of five ester carbonyls at δ~C~ 171.0, 172.1, 172.6, 173.8, and 174.0, led to the assumption that compound **1** is a valtrate hydrin-type iridoid ([@B4]; [@B25]; [@B28], [@B29]; [@B15], [@B15]). It could be seen that the structure of **1** was similar to those of 10-acetoxy-1-acevaltrate hydrin from the ^1^H- and ^13^C-NMR data of **1** ([@B25]), except for the presence of an isovaleroxy residue \[δ~C~ 172.1 (s, C-1′), 44.0 (t, C-2′), 26.8 (d, C-3′), 22.6 (q, C-4′, C-5′) and an α-(isovaleroxy)isovaleroxy group \[δ~C~ 171.0 (s, C-1″), 77.8 (d, C-2″), 31.1 (d, C-3″), 19.3 (q, C-4″), 17.5 (q, C-5″), 174.0 (s, C-6″), 43.8, (t, C-7″), 26.9, (d, C-8″), and 22.7 (q, C-9″, 10″)\] in **1**. The substituent structure of **1** with two isovaleroxy groups located at C-1 and C-7, respectively, was confirmed by the HMBC spectra (**Supplementary Figures [S5](#SM1){ref-type="supplementary-material"}--[S7](#SM1){ref-type="supplementary-material"}**) as following: the correlations (**Figure [2](#F2){ref-type="fig"}**) from H-1 (δ~H~ 6.11, d, *J* = 10.0 Hz), H-2′ (δ~H~ 2.32, m) and H-3′ (δ~H~ 2.04, m) to C-1′ (δ~C~ 172.1, s); from H-7 (δ~H~ 5.48, d, *J* = 2.7 Hz), H-2′″ (δ~H~ 2.28, m) and H-3′″ (δ~H~ 2.15, m) to C-1′″ (δ~C~ 173.8, s). The connection of the α-(isovaleroxy)isovaleroxy functionality to C-10 was fully determined on the basis of the correlations from H-10 (δ~H~ 4.39, 4.35, each d, *J* = 11.3 Hz), H-2″ (δ~H~ 4.78, d, *J* = 4.4 Hz) and H-3″ (δ~H~ 2.26, m) to C-1″ (δ~C~ 171.0, s), together with connections from H-2″ (δ~H~ 4.78, d, *J* = 4.4 Hz), H-7″ (δ~H~ 2.27, m) and H-8″ (δ~H~ 2.11, m) to C-6″ (δ~C~ 174.0, s). The correlations from H-11a (δ~H~ 4.77, d, *J* = 11.4 Hz), H-11b (δ~H~ 4.65, d, *J* = 12.3 Hz) and H-2″″ (δ~H~ 2.00, s) to C-1″″ (δ~C~ 172.6, s) determined the linkage of the AcO residue to C-11.

![Key ^1^H-^1^H COSY (**--**), HMBC (→), and ROESY (↔) correlations of **1** and **2**.](fphar-09-00885-g002){#F2}

The relative configuration of **1** was further established by ROESY experiment (**Figure [2](#F2){ref-type="fig"}** and **Supplementary Figures [S8](#SM1){ref-type="supplementary-material"}, [S9](#SM1){ref-type="supplementary-material"}**) and comparison the spectroscopic data with those reported valepotriates ([@B4]; [@B25]; [@B28], [@B29]; [@B14], [@B15]). Generally, naturally occurring iridoids display α-orientation for H-1 and β-orientation for H-9. In the ROESY spectrum, the correlations of H-9/H-10, OH-8/H-7, not of H-7/H-9 and H-7/H-10 implied that H-9 and H-10 were β-oriented, and H-7 and OH-8 were α-oriented. Comparing the NMR data of **1** with iridoids reported in the literature, the configurations of H-1, H-7, OH-8, H-9, and H-10 were consistent with those valepotriates ([@B4]; [@B28], [@B29]; [@B14], [@B15]). Thus, **1** was assigned as (1*S*, 7*S*, 8*R*, 9*S*)-11-acetoxy-10-\[a-(isovaleroxy)isovaleroxy\]-1, 7-diisovaleroxyvaltrate hydrin, named as jatamanvaltrate T.

Jatamanvaltrate U (**2**) was get as an amorphous white powder, possessed the molecular formula of C~38~H~62~O~10~ by positive-ion HRESIMS at *m*/*z* 701.4234 \[M + Na\]^+^ (calcd 701.4241) (**Supplementary Figure [S13](#SM1){ref-type="supplementary-material"}**). Its IR spectrum (**Supplementary Figure [S20](#SM1){ref-type="supplementary-material"}**) revealed the presence of hydroxy, ester carbonyl and double bond groups from absorption bands at 3444, 1733, and 1642 cm^-1^. Detailed analysis of the ^1^H, ^13^C NMR and DEPT data of **2** (**Table [1](#T1){ref-type="table"}**) (**Supplementary Figures [S14](#SM1){ref-type="supplementary-material"}, [S15](#SM1){ref-type="supplementary-material"}**) revealed that the structure of **2** was similar to those of **1** except for the presence of a palmitoyl group \[δ~H~ 2.32 (2H, t, *J* = 2.4 Hz, H-2″), 1.59 (2H, m, H-3″), 1.28 (each 2H, each m, H-4″∼15″) and 0.88 (3H, t, *J* = 5.6 Hz, H-16″); δ~C~ 175.0 (s, C-1″), 34.5 (t, C-2″), 25.9 (t, C-3″), 30.2-30.7 (t, C-4″-13″), 33.0 (t, C-14″), 23.5 (t, C-15″), and 14.1 (q, C-16″)\] in **2** rather than an α-(isovaleroxy)isovaleroxy in **1**. The HMBC correlations (**Figure [2](#F2){ref-type="fig"}**) of H-10 (δ~H~ 4.31, brs), H-2″ (δ~H~ 2.32, t, *J* = 2.4 Hz) and H-3″ (δ~H~ 1.59, m) with C-1″ (δ~C~ 175.0, s), of H-11a (δ~H~ 4.76, d, *J* = 12.3 Hz), H-11b (δ~H~ 4.65, d, *J* = 12.3 Hz), and H-2″″ (δ~H~ 2.00, s) with C-1″″ (δ~C~ 172.6, s) indicated the palmitoyl and acetoxyl residue were located at C-10 and C-11 of **2**, respectively. Furthermore, the positions of the other two isovaleroxy groups at C-1 and C-7 were also confirmed based on the HMBC correlations (**Supplementary Figures [S16](#SM1){ref-type="supplementary-material"}--[S18](#SM1){ref-type="supplementary-material"}**).

By comparison of the ROESY correlations (**Supplementary Figure [S19](#SM1){ref-type="supplementary-material"}**) with that of **1**, the relative configuration of **2** (**Figure [2](#F2){ref-type="fig"}**) was demonstrated to be identical to that of **1**. All of the key ROESY correlations of H-9/H-10, OH-8/H-7 supporting the structure of **1** were also observed in **2**, suggesting that the H-9 and H-10 were β-oriented and H-7 and OH-8 were α-oriented. Therefore, **2** was established as (1*S*, 7*S*, 8*R*, 9*S*)-11-acetoxy-1,7-di isovaleroxy-10-palmitoyl caltrate hydrin, named as jatamanvaltrate U.

The known compounds, valtrate hydrin B8 (**3**) ([@B4]), volvaltrate B (**4**) ([@B14]), deoxido-didrovaltrate (**5**) ([@B2]), baldrinal (**6**) ([@B5]), homobaldrinal (**7**) ([@B5]), desacylbaldrinal (**8**) ([@B8]), 11-methoxyviburtinal (**9**) ([@B3]), jatamanvaltrate R (**10**) ([@B6]), jatamanvaltrate S (**11**) ([@B6]) rupesin E (**12**) ([@B13]), (1S, 3R, 5S, 7S, 8S, 9S)-3, 8-epoxy-7-hydroxy-1-methoxy-4, 11-dihydronepetane (**13**) ([@B26]), valeriananoid B (**14**) ([@B19]), valeriananoid C (**15**) ([@B19]), valeriananoid D (**16**) ([@B6]), and valeriananoid E (**17**) ([@B6]) were identified by analysis of their spectroscopic data and comparison with the literature values. This is the first isolation of iridoids with fatty acid esters (**2**) from the family of Valerianaceae.

Functional Characterization of Isolated Compounds
-------------------------------------------------

The traditional use of the roots and rhizomes of *V. jatamansi* to treat abdominal pain led us to assume that some of their effects may be mediated through inhibition of Ca~v~2.2. Therefore, we carried out a systematic functional assay of the various extracts, fractions and isolated compounds obtained from the herbal medicine. Initially, we found that the ethanol extract and its EtOAc-soluble layer (0.01 mg/ml) showed inhibitory effects of 36 and 49% on Ca~v~2.2, respectively, while the *n*-BuOH and H~2~O layers (0.01 mg/ml) exhibited negligible activities (**Table [2](#T2){ref-type="table"}**). Of all the fractions from the ethyl acetate extract, fractions 4 and 6 exhibited strongest activities on Ca~v~2.2, with 68.6 ± 3.1% and 60.1 ± 4.0% inhibition at 0.01 mg/ml, respectively (**Table [2](#T2){ref-type="table"}**). Further phytochemical isolation from these two fractions led to the discovery of two new valepotriates, jatamanvaltrate T and U (**1**--**2**) and fifteen known compounds (**3**--**17**). All of the isolates were evaluated for their inhibitory effects on Ca~v~2.2. The new compound **1** (jatamanvaltrate T) and the main constituent **3** showed prominent inhibition of Ca~v~2.2 (**Table [2](#T2){ref-type="table"}** and **Figure [3](#F3){ref-type="fig"}**). Other compounds produced no (**10**--**17**) or much weaker (**2, 4**--**9**) effects on Ca~v~2.2, even at a concentration of 30 μM (**Table [2](#T2){ref-type="table"}**) (**Supplementary Figure [S26](#SM1){ref-type="supplementary-material"}**). Based on the bioassay results and the structure of these compounds, we postulate that the diene-type iridoid is a nucleus for the inhibitory activity on Ca~v~2.2.

###### 

Effect of extracts and compounds 1-9 on Ca~v~2.2 N-type VGCC.

  Fraction        Ca~v~2.2^a^ (N-type)   Compound   Ca~v~2.2^b^ (N-type)
  --------------- ---------------------- ---------- ----------------------
  EtOH extract    36.3 ± 10.2%           **1**      43.8 ± 1.7%
  EtOAc-part      48.6 ± 7.7%            **2**      3.2 ± 2.1%
  *n*-BuOH-part   --                     **3**      38.9 ± 6.7%
  H~2~O-part      1.1 ± 1.7%             **4**      4.1 ± 2.4%
  **Fr.1**        1.3 ± 6.3%             **5**      9.0 ± 16.2%
  **Fr.2**        56.5 ± 4.8%            **6**      8.5 ± 7.0%
  **Fr.3**        10.5 ± 6.2%            **7**      0.1 ± 1.1%
  **Fr.4**        68.6 ± 3.1%            **8**      3.4 ± 1.9%
  **Fr.5**        55.2 ± 3.5%            **9**      5.4 ± 1.5%
  **Fr.6**        60.1 ± 4.0%                       
  **Fr.7**        34.1 ± 6.3%                       
  **Fr.8**        28.4 ± 5.2%                       
  **Fr.9**        14.1 ± 2.0%                       

a

Peak current inhibition ratio of extracts at 0.01 mg/ml;

b

Peak current inhibition ratio of compounds at 10 μM (

1

and

3

) or 30 μM (other compounds); Data represent the mean ± SEM of 3 or 4 cells.

![Inhibitory effects of compounds **1** and **3** on Ca~v~2.2 and their selectivity. **(A)** Representative Ca~v~2.2 current traces evoked by a 50-ms depolarization to +20 mV at 3-s intervals from a holding potential (HP) of --80 mV in the presence of the indicated compounds. Ca~v~2.2 was expressed in *Xenopus* oocytes. **(B)** Dose--response relationships of the indicated compounds for Ca~v~2.2 at a HP of --80 mV. Data points represent mean ± SEM of three or five measurements. Solid curve represents a fit to a modified Hill equation with an EC~50~ of 3.3 μM (**1**) and 4.8 μM (**3**), and a Hill coefficient of 0.82 (**1**) and 0.93 (**3**). **(C,D)** Effects of compounds **1** and **3** on indicated ion channels. The effect on the peak current was determined for each compound at 10 μM (N-, L-, P/Q- and T-type VGCCs) and 30 μM (BK, K~v~1.1, K~v~2.1, and K~v~3.1 potassium channels). Data represent mean ± SEM (*n* = 3). ^∗∗^*P* \< 0.01 according to the two-tailed Student's *t*-test.](fphar-09-00885-g003){#F3}

The inhibition of Ca~v~2.2 by compounds **1** and **3** was dose-dependent, with an EC~50~ of 3.3 μM (*n* = 5) and 4.8 μM (*n* = 3), respectively (**Figure [3](#F3){ref-type="fig"}**). Interestingly, the inhibition by both compounds was incomplete, plateauing at ∼65% at a near saturation concentration of 100 μM (**Figure [3](#F3){ref-type="fig"}**). This result suggests that compounds **1** and **3** act allosterically to modulate Ca~v~2.2 gating rather than block channel conduction.

We also tested the effect of compounds **1** and **3** on several other types of VGCCs, including L-type (Ca~v~1.2), P/Q-type (Ca~v~2.1) and T-type (Ca~v~3.1), and on several types of potassium channels, including Kv1.1, Kv2.1, Kv3.1 and BK channels (**Table [3](#T3){ref-type="table"}** and **Figures [3C,D](#F3){ref-type="fig"}**). At 10 μM, 1 and 3 showed substantially weaker inhibitory effects on Ca~v~1.2, Ca~v~2.1, and Ca~v~3.1 (**Table [3](#T3){ref-type="table"}** and **Figures [3C,D](#F3){ref-type="fig"}**). At 30 μM, compound 1 had negligible effects on Kv1.1, Kv2.1, and Kv3.1 channels (**Table [3](#T3){ref-type="table"}** and **Figure [3C](#F3){ref-type="fig"}**), although both compounds 1 and 3 showed weak inhibition on the BK channel (**Table [3](#T3){ref-type="table"}** and **Figure [3D](#F3){ref-type="fig"}**).

###### 

Effect of 1 and 3 on selected types of VGCCs and potassium channels.

  Compound   Ca~v~1.2^a^ (L-type)   Ca~v~2.1^a^ (P/Q-type)   Ca~v~3.1^a^ (T-type)   BK^b^ channel   K~v~1.1^b^   K~v~2.1^b^   K~v~3.1^b^
  ---------- ---------------------- ------------------------ ---------------------- --------------- ------------ ------------ ------------
  1          10.1 ± 1.2%            1.3 ± 0.3%               11.8 ± 2.9%            15.5 ± 1.0%     2.8 ± 1.1%   1.0 ± 1.1%   0.5 ± 0.5%
  3          13.5 ± 4.1%            7.8 ± 1.2%               20.4 ± 7.4%            6.7 ± 7.7%      --           --           --

a

Peak current inhibition ratio of compounds at 10 μM;

b

Peak current inhibition ratio of compounds at 30 μM; "-" not tested, due to the limited amount of material. Data represent the mean ± SEM of 3 or 4 cells.

In a positive control experiment, we tested the effect of two known N-type VGCC inhibitors, the divalent cation cadmium (Cd^2+^), which is a broad pore blocker of VGCCs, and the marine cone snail peptide toxin ω-conotoxin MVIIA, which is an N-type VGCC antagonist. As expected, both molecules inhibited Ca~v~2.2 currents in *Xenopus* oocytes and HEK 293T cells (**Supplementary Figures [S27](#SM1){ref-type="supplementary-material"}, [S28](#SM1){ref-type="supplementary-material"}**).

In summary, our study shows that valepotriates, one of the main constituents of the *V. jatamansi*, can inhibit Ca~v~2.2 N-type VGCCs. This activity is consistent with the analgesic effect of *V. jatamansi* in alleviating abdominal distention and pain. Further bioassay-guided search in *V. jatamansi* may yield more compounds that target N-type VGCCs.
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